Problem

Evolvere BioSciences addresses antimicrobial resistance: bacteria evolve around existing antibiotics, causing treatments to stop working and forcing society into a costly cycle of repeated drug discovery. The burden is both clinical and economic: bacterial antimicrobial resistance was associated with more than 4.7 million deaths globally in 2021, while unchecked resistance has been estimated to threaten 3.8% of global GDP annually by 2050 and increase healthcare costs from roughly $66 billion to $159 billion.

The central use case is treating serious bacterial infections—especially infections caused by resistant pathogens—without the collateral damage of broad-spectrum antibiotics. Evolvere’s stated goal is to create therapies that precisely target pathogenic bacteria while sparing beneficial microbes and human cells, and that remain effective against the mutations bacteria are likely to develop.

Product / Service

Evolvere combines evolutionary biology, computational models, and AI to design next-generation protein antibiotics. Its approach uses co-evolutionary protein-interaction data to forecast bacterial mutations, then subjects large libraries of antibiotic candidates to iterative mutation and selection for stronger antibacterial activity and reduced resistance. The company describes this as a new modality of protein antibiotic therapy intended to outpace bacterial evolution.

The business appears to have a dual model: developing therapeutic antibiotic assets while licensing its AI and computational design tools. Its protein-design platform has been deployed on AWS using orchestrated compute and storage workflows, with generative design, inverse-folding, structure-prediction, and biophysical-evaluation steps. The intended benefit is a more targeted and durable antibiotic-discovery process, potentially reducing how often entirely new antibiotics must be developed.

Market

Evolvere competes in TechBio and AI-powered drug discovery, specifically the next-generation and precision-antibiotics segment. Its adjacent competitive set includes Glox Therapeutics, which is developing engineered protein bacteriocins; Phare Bio, which is building a generative-AI antibiotic discovery engine; and Locus Biosciences, which is developing engineered bacteriophage therapies against bacterial pathogens. Evolvere’s differentiator is its emphasis on forecasting bacterial evolution and designing protein antibiotics to minimize future resistance, rather than relying only on conventional antibiotic discovery or pathogen-targeting modalities.

The company is an early-stage Oxford biotech founded in 2021, accepted into Y Combinator’s Summer 2024 cohort, and listed as active with a three-person team. PitchBook reports $511,000 raised, while AWS documented deployment of its protein-design platform. The evidence reviewed does not disclose a clinical-stage candidate, approved product, or named commercial customer, so the most defensible characterization is pre-commercial and early-stage rather than definitively pre-revenue; one third-party directory estimates revenue, but that estimate is not corroborated by a primary company source.